Malaysia's BiotechCorp Sees More Than Double Revenue Target Achieved
This article was originally published in PharmAsia News
Executive Summary
The state-run Malaysian Biotechnology Corp said the companies it supports under BioNexus are expected to reach combined foreign investments of nearly $1 billion by the end of the year, in contrast to last year's $340 million.